ESR1 mutations provide novel targets for breast cancer immunotherapy.

3135Background: Estrogen receptor (ER)-positive breast cancer is not considered immunogenic. Standard treatment is endocrine therapy to include aromatase inhibitors (AI). However, constitutively ac...